Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. by Müller, W. et al.
British Journal of Cancer (1996) 74, 759-765
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 9
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Summary The prognostic significance of tumour cell proliferation was investigated in a series of 418 gastric
carcinomas using the monoclonal antibody MIB-1. Owing to strong intratumoural heterogeneity of MIB-1
expression three different proliferation indices (PIs) were determined in all carcinomas: (1) PImax in areas of
maximal tumour cell proliferation, (2) PIrand in areas randomly distributed over the whole tumour, (3) Plfront in
areas exclusively located at the tumour invasion front. There was a strong intertumoral heterogeneity with
PImax ranging from 4.9% to 92.2%, Plrand ranging from 3.4% to 81.4% and PIfr.nt ranging from 4.2% to
87.1%. The mean values were 51.3% + 19.7 for Plmax, 34.2% + 18.3 for Plrand and 37.2%+ 19.5 for PIfront.
Whereas no statistically significant correlation could be found between proliferative activity and the
clinicopathological parameters depth of invasion, lymph node involvement or grade of tumour differentiation,
there was a positive correlation between a high proliferation index at the tumour invasion front (PIfr.nt) and the
presence of blood or lymphatic vessel invasion. No significant correlation could be demonstrated between the
different proliferation indices and survival, even when different subgroups of patients were analysed separately.
The present results suggest that the immunohistochemical evaluation of the proliferation activity has no
predictive value for the prognosis of gastric cancer patients or the identification of subgroups of patients who
may be at higher risk.
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High proliferative activity has been shown to correlate with
poor clinical outcome in a variety of human malignancies
such as breast cancer (Tubiana et al., 1989; Gasparini et al.,
1992a; Aaltomaa et al., 1993; Siitonen et al., 1993; Railo et
al., 1993; Haerslev and Jacobsen, 1994), colon cancer (Al-
sheneber et al., 1993; Mayer et al., 1993), lung cancer (Fujii et
al., 1993), bladder cancer (Skopelitou et al., 1992; Lipponen
et al., 1992; Mulder et al., 1992), prostatic cancer (Harper et
al., 1992) or ovarian cancer (Isola et al., 1990; Jordan et al.,
1993; Kerns et al., 1994; Henriksen et al., 1994; Thomas et
al., 1995). Nevertheless, studies lacking such a correlation
between tumour cell proliferation and prognosis have also
been reported in the same tumour entities (Hemming et al.,
1992; Kubota et al., 1992; Gasparini et al., 1992b; Cummings
et al., 1993; Thomas et al., 1993).
Investigations on tumour cell proliferation have also been
carried out in gastric cancer (Yonemura et al., 1990a,b, 1991,
1993; Porschen et al., 1991; Jain et al., 1991; Kakeji et al.,
1991; Mori et al., 1993), only some of which have also
focused on its prognostic role. Whereas Yonemura et al.
(1990a) as well as Mori et al. (1993) stressed the proliferative
activity as an independent prognostic parameter in gastric
cancer, Jain et al. (1991) failed to show this correlation. A
positive correlation shown in another study (Yonemura et al.,
1993) was limited to biopsy material of advanced gastric
cancers and could not be confirmed by multivariate analysis.
Finally, in another study on gastric carcinomas tumour cell
proliferation was shown to be correlated with a worse
prognosis (Maeda et al., 1995), but there was a strong
predominance of late-stage tumours with serosal infiltration
in this study.
Most of these investigations are immunohistochemical
studies using antibodies against the Ki-67 antigen or the
proliferating cell nuclear antigen (PCNA). The Ki-67 antigen
is present in all stages of the cell cycle except Go (Gerdes et
al., 1984) and the Ki-67 antibody is the most reliable
antibody for assessing the growth fraction by immunohis-
tochemistry (Brown and Gatter, 1990; Quinn and Wright
1990). However, it only works on cryostat sections, thus
limiting its application in routine pathology and archival
paraffin blocks. The PCNA antibody has the advantage of
working on formalin-fixed and paraffin-embedded sections,
however, PCNA expression is not only associated with
DNA synthesis, but also dependent on other factors, e.g. its
synthesis can be induced by various growth factors (Bravo,
1986; Macdonald-Bravo and Bravo, 1985). Recently, a
novel antibody (MIB-1) was generated against the Ki-67
antigen, which is suitable for paraffin sections after
microwave processing. Thus, MIB-1 combines the advan-
tages of the Ki-67 and PCNA antibodies, being a reliable
marker of proliferation for easy assessment of the growth
fraction on paraffin-embedded tissue (Key et al., 1992;
Cattoretti et al., 1992). Owing to the contradictory results
concerning gastric carcinoma, we investigated the prognostic
role of tumour cell proliferation in a large retrospective




The present study is based on 529 consecutive patients
undergoing potentially curative surgery for gastric cancer
from January 1980 to December 1988. Curative surgery was
defined as the removal of all gross tumours and the
demonstration of tumour-negative surgical margins by
microscopic examination of the total circumference of the
gastric resection line (RO resection). Total gastrectomy was
performed in 315 patients (59.5%), subtotal resection in 214
patients (40.5%), 327 patients (61.8%) were male and 202
(38.2%) were female. The mean age was 64.9 years ranging
from 23 to 90 years. Follow-up letters were sent to the
surgeons or local tumour registers to obtain up-to-date
information on survival and relapse or death. Twenty-one per
cent of the patients were lost to follow-up, leaving 418
patients for the final study and statistical evaluation. None of
the patients received adjuvant chemotherapy. In order to
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eliminate bias due to deaths directly resulting from operation,
patients who died within 4 weeks after surgery were excluded
from the survival analysis.
Pathological review
The surgical specimens were fixed in formalin overnight at
room temperature and embedded in paraffin. An average of
four sections per tumour wasprepared and theparaffin sections
were routinely stained with haematoxylin eosin (HE) and
periodic acid Schiffreaction (PAS). All sections were reviewed
without knowledge of the clinical outcome. The histological
type of the tumour was determined according to the WHO
classification (Oota and Sobin, 1977) and the Lauren
classification (Lauren, 1965). To compare the prognostic
significance of the proliferative activity as determined by
MIB-1 expression with known prognostic parameters, the
following morphological features were recorded: depth of
invasion (pT category; International Union Against Cancer,
Hermanek and Sobin, 1987), lymph node involvement (pN
category), grade of tumour differentiation as well as blood
vessel invasion (BVI) and lymphatic vessel (LVI) invasion
(Gabbert et al., 1991). Tissue for a pathohistological
verification of distant metastasis (pM category) could only be
obtained in 23 out of the 418 patients, so this parameter was
excluded from further evaluation.
Immunohistochemistry
From each patient one representative tumour block including
tumour centre and invasion front as well as tumour-
associated non-neoplastic mucosa were examined by immu-
nohistochemistry. In cases of large late-stage tumours (pT3
and pT4) different sections were examined to include
representative areas from the tumour centre as well as from
the lateral and deep tumour invasion front. The formalde-
hyde-fixed paraffin sections were stained for MIB-1 using the
avidin-biotin complex (ABC) technique after microwave
pretreatment, three times for 5 min at 600 W (citrate buffer,
pH 6.0). The primary antibody was diluted 1:10 with
phosphate-buffered saline (PBS) and the slides were then
counterstained with haemalaune.
Tonsils and lymph nodes from separate paraffin blocks
were used as positive controls. Additionally, MIB-1 staining
in adjacent non-neoplastic gastric mucosa present in all ofthe
investigated tumour blocks served as a further internal
positive control. Negative controls were performed by
replacing the primary antibody through PBS. All slices were
evaluated without knowledge of the clinical outcome.
MIB-1-positive cells showed a distinct brown staining ofthe
nuclei with a strong intratumoral heterogeneity (Figure 1).
Only nuclear staining was accepted as positive and all labelled
tumour cell nuclei were regarded as positive. No differences
could be found in staining intensitywhen tumours from 1980 to
84 and those from 1985 to 88 were compared, thus excluding a
possible influence ofageing on the stored materials.
Proliferation index (PI)
The MIB-l proliferation index (PI) was calculated as the
percentage of MIB-l-positive tumour cell nuclei determined
in at least ten high-power fields (HPFs) by counting at least
1000 tumour cells. All tumour cell counts were made at
400 x magnification using a 10 x 10 mm square grid that had
been placed in the eyepiece.
Owing to the strong intratumoral heterogeneity of tumour
cell proliferation three different proliferation indices were
defined (Figure 2). (1) PI maximum (PIm,,,) was determined in
at least ten HPFs suggested to have the highest labelling
index when the tumour was prescored at low magnification.
(2) PI random (PIrand) was evaluated in at least ten HPFs
chosen at random. (3) PIfront was determined in at least ten
HPFs exclusively located at the lateral or deep invasion front
of the tumours.
The median value of each of the three different PI values
was used as a cut-off value to discriminate between tumours
with a high PI (>median PI) and those with a low PI
(<median PI).
Statistical analysis
Tests for differences between the groups with a high and low
PI were performed using Fisher's exact test for dichotomous
variables, the chi-square test for other categorical variables
and the Wilcoxon-Mann-Whitney test for ordinal variables.
Analyses of survival were performed using the Kaplan-
Meier method (Kaplan and Meier, 1958) and differences
between the patient groups were tested by the log-rank test
(Kalbfleisch and Prentice, 1980). Differences with P-values
<0.05 were considered as significant.
Results
The activity of tumour cell proliferation strongly differed
between individual tumours, the lowest PI in a tumour being
3.4%, the highest 92.2% (Table I). Furthermore, there was a
strong intratumoral heterogeneity of tumour cell prolifera-
tion, the mean values of the proliferation indices being 51.3%
in areas of maximal proliferation, 34.2% in randomly
selected areas and 37.2% in areas at the tumour invasion
front.
In the non-neoplastic gastric mucosa adjacent to the
tumour, MIB-1 expression was only detected in a few cells of
the proliferation zone at the neck of the gastric glands.
Figure 1 Gastric adenocarcinoma of the so-called intestinal type
according to Lauren with a strong heterogeneous MIB-1
expression (MIB-1, ABC technique, scale bar: lOOm).
Figure 2 PI values determined in all 418 gastric carcinomas.
PImax: areas of maximal proliferation, for example here located in
the tumour centre (-). PIrand: areas randomly distributed over
the tumour (0). PIfront: areas exclusively located at the lateral
and deep tumour invasion front (A).Proliferaton and prognosis In gastric cancer
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Correlation with other histopathological parameters
With regard to the Lauren classification (Table II), the PI
indices were significantly higher (P<0.0001) in carcinomas of
the so-called intestinal type (mean Plmax 56.5%) than in
carcinomas of the diffuse type (mean PI,,., 39.7%). The same
was true for the PIs evaluated randomly and at the invasion
front. According to the WHO classification adenocarcinomas
of the papillary type (mean PI,,, 61.5%) and tubular type
(mean Plmax 55.3%) similarily showed a higher proliferative
activity (P<0.0001) than signet-ring cell carcinomas (mean
Pimax 40.1%). The same was true for the mean values of
PIfront and PIrand (Table II).
In contrast, no significant correlation was observed when
tumour cell proliferation was correlated with depth of
invasion (pT category), lymph node involvement (pN
category), stage of disease (UICC classification) or grade of
tumour differentiation (Table II).
Concerning blood vessel invasion (BVI) and lymphatic
vessel invasion (LVI) a positive correlation was found for the
PI determined at the invasion front of the tumours (P=0.001
and P=0.002 respectively), but not for Plma, and PIrand. Thus,
tumours with a higher tumour cell proliferation at the
invasion front significantly more often showed blood vessel
invasion and lymphatic vessel invasion than those with a low
PI (Table III).
Survival analysis
As shown by the log-rank test no significant differences in the
survival rates exist between tumours with PIs higher than the
Table I Proliferation indices in 418 gastric carcinomas
Mean (%) s.d. (%) Median (%) Range (%)
PImax 51.3 ± 19.7 53.3 4.9-92.2
PIrand 34.2 ± 18.3 32.0 3.4-81.4
Plfront 37.2 + 19.5 34.9 4.2-87.1
median values and those with a PI lower than the median
values (Table IV and Figure 3). This was true for the
maximal PI (PImax) as well as for the PI evaluated in
randomly selected areas (PIrand) and in areas at the tumour
invasion front (PIfront). No differences in prognosis were
found either when different cut-off levels (PI 10%, 20-80%)
were calculated instead of the median values (data not
shown).
To correlate the potential prognostic value of tumour cell
proliferation in different subgroups of patients the survival
data were separately calculated for the subgroup of pTl and
pT2 tumours and for the subgroup ofadvanced pT3 and pT4
tumours. Patients with pTI and pT2 tumours had a
significantly better prognosis than patients with pT3 and
pT4 tumours (P<0.0001), the proliferative activity, however,
did not influence the prognosis in the subgroup of pTI and
pT2 tumours or in the subgroup of advanced pT3 and pT4
Table m Proliferation indices and correlation with vascular
invasion
LVI-positive tumours BVI-positive twnours
(%o) (%)
Plmax
<Median (n = 207) 45.2 20.4
> Median (n=211) 50.2 28.0
P = 0.327 P = 0.086
PIrand
<Median (n = 208) 46.6 23.1
>Median (n = 210) 48.8 25.4
P = 0.695 P = 0.648
PIfront
<Median (n = 208) 40.1 17.4
>,Median (n = 210) 55.2 31.0
P= 0.002 P= 0.001
LVI, lymphatic vessel invasion; BVI, blood vessel invasion.
Table H Proliferation indices and correlation with other parameters in 418 gastric carcinomas
Mean PI values (%)
(n) PImax PIfront PIrajd
Lauren classification
Intestinal 264 56.5+ 17.4a 42.0+ 18.7 38.9+17.9
Diffuse 117 39.7+19.5 25.5+15.6 22.8+13.3
Indetermined 37 51.5±20.9 39.7+21.6 36.1± 19.4
WHO classification
Signet-ring 112 40.1±20.6 25.4+ 16.6 22.9+14.8
Papillar 39 61.5+14.7 45.5+17.2 40.9+16.6
Tubular 163 55.3+ 15.6 40.1+17.9 37.5+16.8
Mucinous 34 51.1+21.3 36.9±18.6 35.8+18.3
Undifferentiated 70 54.6±20.7 45.1 +20.9 40.1 + 19.8
pT category
pTl 97 46.2±20.8 29.4+ 17.9 30.0+ 17.5
pT2 188 53.7+18.8 42.1+19.4 37.9+18.1
pT3/4b 133 51.6±19.7 36.0+19.0 31.9+18.1
pN category
Lymph node negative 189 51.2±20.2 36.9±19.7 34.6+18.3
Lymph node positive 229 51.4+19.4 37.5+19.5 33.9+ 18.3
pTNM category
Stage I 173 50.0±20.1 36.4+19.8 34.8+18.3
Stage II 119 52.7±19.1 39.2+19.2 34.5+18.1
Stage III 109 52.0+ 19.0 36.4± 18.9 33.1+ 17.8
Stage IV 17 48.6±24.1 36.2+22.1 32.9+21.5
Grading
Glc/G2 112 58.7± 15.9 41.9±18.9 39.1+17.8
G3 227 46.6± 19.6 32.4+ 18.0 30.0+ 16.8
G4 79 54.5±21.4 44.3i21.3 39.4+20.1
aStandard deviation. bpT4 only five tumours. cGI only one tumour.
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Table IV Proliferation indices and correlation with the median survival times and 5
year survival rates in 418 gastric carcinomas
Median survival times Five year survival
n (years) rates (%) P-value
Pimax
<53.3% 207 2.73 44.8 0.84
>53.3% 211 2.95 43.1
Plrand
<32.0% 208 3.21 46.8 0.38
32.0% 210 2.31 41.4
Plfront
<34.9% 208 3.48 48.5 0.16
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Figure 3 Survival curves of 418 gastric cancer patients. No
statistically significant differences between tumours with max-
imum proliferative activity (Plmax) higher and lower than the
median value.
tumours (Table V). The same was true for the pN category.
Among the 418 patients included in this investigation, the 189
lymph node-negative patients had a significantly better
prognosis than the 229 lymph node-positive patients
(P=0.0001). Tumour cell proliferation, however, had no
influence on survival in the subgroup of lymph node-negative
patients or in that of lymph node-positive patients (Table
VI).
Discussion
The proliferation rate of tumours has long been considered to
reflect the course and prognosis of tumour disease. Various
methods have been described and, besides the mitotic count,
immunohistochemical assessment of the growth fraction
seems to be the easiest method for routine pathology. The
monoclonal Ki-67 antibody has been shown to be a most
reliable marker of cell proliferative activity, however, its use
is limited to frozen tissue sections (Brown and Gatter, 1990).
This major drawback has been overcome by the monoclonal
antibody MIB-1, which is able to recognise the Ki-67 antigen
on formalin-fixed and paraffin-embedded tissue sections.
Thus, it is now possible to investigate the growth fraction
on sufficiently large retrospective tumour series with routine
methods in order to study the correlation of tumour cell
proliferation with histopathological features and prognosis of
the tumours.
Nevertheless, there are several problems that can affect the
use of MIB-1 as a prognostic parameter. Most tumours
consist of a heterogeneous cell population and, also, tumour
cell proliferation is known to exhibit a most conspicious
intertumoral and intratumoral heterogeneity (Kerns et al.,
1994; Thomas et al., 1995; Hemming et al., 1992; Mori et al.,
1993). In the present study on 418 gastric carcinomas a
similar heterogeneity became evident with a PI ranging from
3% to 92% proliferating tumour cells in different carcinomas.
Furthermore, a conspicious intratumoral heterogeneity was
found with a mean proliferative activity of 51.3% in areas of
maximum proliferation in contrast to 34.2% in areas
randomly selected over the tumour and 37.2% in areas
located at the tumour invasion front. This heterogeneity may
represent true clonal subpopulations of tumour cells that
have accquired a growth advantage. However, it cannot be
ruled out that this heterogeneity is only temporary,
depending on local factors such as growth factors that may
influence the activity of tumour cell proliferation. Thus, this
strong intratumoral heterogeneity limits the evaluation of
tumour cell proliferation in gastric biopsies.
Concerning the correlation of tumour cell proliferation
with clinicopathological parameters, contradictory results
have been reported in gastric cancer using either Ki-67
(Yonemura et al., 1990a, b, 1991; Kakeji et al., 1991;
Porschen et al., 1991) or PCNA (Jain et al., 1991; Mori et
al., 1993; Yonemura et al., 1993; Maeda et al., 1995). In the
present study we were able to show a statistically significant
correlation between tumour cell proliferation and histological
tumour type according to the Lauren classification. Thus,
tumours with a glandular appearance of the so-called
intestinal type showed significantly higher PI values than
carcinomas of the diffuse type. Similarly, the papillary and
tubular carcinomas of the WHO classification showed a
statistically significant higher PI value than signet-ring cell
carcinomas. In other studies on gastric cancer, tumour cell
proliferation was not correlated with the WHO classification
but with the Lauren classification in the studies of Jain et al.
(1991) as well as Mori et al. (1993). In both of these studies,
using the PCNA antibody, the intestinal-type carcinomas also
had a higher growth fraction than the diffuse-type
carcinomas, although the difference did not reach statistical
significance. Furthermore, it was shown that in experimen-
tally induced colon carcinomas also, the undifferentiated
tumours exhibited a statistically significant lower tumour cell
proliferation than differentiated gland-building tumours
(Gabbert et al., 1982). We can only speculate on the reasons
for the different proliferative status of such distinct
histiotypes, but we must also consider that the evaluation
of proliferative activity by immunohistochemistry can only
assess the growth fraction but not the time that the tumour
cells take to complete the cell cycle. Thus, a tumour with only
a few MIB-1-positive tumour cells but a short cell cycle time
may have a higher proliferation rate than a tumour in which
nearly all tumour cells are in cycle (and MIB-1 positive) but
take a long time to complete it.
Concerning known prognostic parameters in gastric
cancer, no correlation was found in our study between the
proliferative activity and depth of invasion (pT category),
lymph node involvement (pN category) and grade of
differentiation. This was true for PIs evaluated in the areas
of highest proliferative activity as well as for PIs evaluated
randomly or at the tumour invasion front. Although these
60
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Table V Proliferation indices and correlation with the median survival times and 5
year survival rates depending upon the pT category
Median survival times Five year survival
n (years) rates (%) P-value
Plmax
pTl + pT2
<53.3% 140 ND 57.2 0.90
>53.3% 145 5.85 52.4
pT3 + pT4
<53.3% 67 1.30 17.6 0.84
>53.3% 66 1.02 22.4
PIrand
pTl + pT2
<32.0% 132 ND 58.8 0.45
>32.0% 153 5.85 51.7
pT3 + pT4
<32.0% 77 1.40 24.6 0.06
>32.0% 56 0.99 10.2
PIfront
pTl + pT2 139 ND 60.2 0.19
<34.9%
>34.9% 146 5.85 50.0
pT3 + pT4
<34.9% 69 1.36 24.1 0.23
>34.9% 64 1.02 13.1
ND, not determined, no drop under the 50% level ofsurvival.
Table VI Proliferation indices and correlation with the median survival times and 5
year survival rates depending upon the pN category
Median survival times Five year survival
n (years) rates (%) P-value
PImax
Node negative
<53.3% 90 ND 69.7 0.70
>53.3% 99 ND 61.0
Node positive
<53.3% 117 1.72 26.8 0.83
>53.3% 112 1.30 26.2
Pirand
Node negative
<32.0% 90 ND 69.4 0.23
>32.0% 99 ND 61.6
Node positive
<32.0% 118 1.57 27.8 0.66
>32.0% 111 1.36 24.5
Plfront
Node negative
<34.9% 98 ND 67.7 0.56
>34.9% 91 ND 62.9
Node positive
<34.9% 109 1.72 31.6 0.21
>34.9% 120 1.35 20.9
ND, not determined, no drop under the 50% level ofsurvival.
findings are in accordance with those of some other studies
using Ki-67 (Yonemura et al., 1990a; b, 1991), a positive
correlation between a high PI and pT category was also
reported using Ki-67 (Kakeji et al., 1991) or PCNA (Mori et
al., 1993; Yonemura et al., 1993), whereas Jain et al. (1991)
reported a higher tumour cell proliferation index in lower pT
categories using PCNA.
In our study a statistically significant correlation was
found between tumour cell proliferation at the invasion front
and the presence of blood or lymphatic vessel invasion, which
has been shown in the same population of patients to be
important prognostic factors in gastric carcinomas (Gabbert
et al., 1991). This result is consistent with several of the
previous studies also reporting a positive correlation between
vascular invasion and a high proliferative activity for Ki-67
(Yonemura et al., 1991; Kakeji et al., 1991) and PCNA (Mori
et al., 1993). Nevertheless, we could not find a significantly
higher percentage of lymph node metastases in the tumours
with a high proliferative activity.
Accordingly, no impact of tumour cell proliferation on
survival could be verified in our study. Although this lack of
prognostic significance of tumour cell proliferation was trueProliferation aNd ironos gashric cancer
W Muler et al
764
for all three proliferation indices (PIa., PId, PIfr00t)
investigated in our study. there is a contrast to some
previous studies showing a correlation between high tumour
cell proliferation and poor prognosis in univariate analysis
using PCNA (Yonemura et al.. 1993) and in multivarate
analysis using Ki-67 (Yonemura et al., 1990a) or PCNA
(Mon et al.. 1993; Maeda et al.. 1995). These studies.
however. included only small numbers of patients and were in
part limited to advanced carcinomas. most of them with
serosal infiltration (Yonemura et al.. 1990a: Maeda et al..
1995). To consider this aspect of our study the prognostic
impact of tumour cell proliferation was separately analysed in
the subgroup of pT1 and pT2 tumours and in the subgroup
of advanced pT3 and pT4 tumours as well as in node-
negative and node-positive patients. A statistically significant
impact of tumour cell proliferation on survival could be
verified in none of these subgroups, however.
Looking at the literature, tumour cell proliferation has
been shown to be an independent prognostic parameter in
gastric cancer in three studies. each comprising about 90
cases ofgastric carcinoma. The reasons why our study on 418
gastnc carcinomas could not confirm this finding can only be
speculative, but tissue fixation. different antibodies and
different methods of evaluating the proliferating tumour
cells are known to influence the assessment of tumour cell
proliferation as a prognostic marker. Furthermore, the cell
cycle time, which cannot be measured by MIB-1 immuno-
histochemistry, might be more important for biological
behaviour than the pure growth fraction of tumour cells.
As a main result from our study. it seems reasonable.
however, that. at least in gastric cancer, the factors that lead
to more aggressive tumour growth with early recurrence or
metastases are not related to the growth fraction as
determined by immunohistochemical methods alone.
In summary, according to the results of the present
retrospective study. the immunohistochemiical detection of
MIB-1 is a valuable tool for evaluating proliferative activity
in formalin-fixed tumour tissue. Nevertheless, in our series of
418 gastric carcinomas, tumour cell proliferation had no
impact on the prognosis; neither was it a useful tool for
defining subgroups of patients who may be at a higher risk.
Our retrospective study may. nevertheless, encourage further
investigations under prospective conditions.
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